Intervention Review

You have free access to this content

Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus

  1. Kurinchi Selvan Gurusamy1,*,
  2. Emmanuel Tsochatzis2,
  3. Clare D Toon3,
  4. Elias Xirouchakis4,
  5. Andrew K Burroughs5,
  6. Brian R Davidson1

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 4 DEC 2013

Assessed as up-to-date: 14 FEB 2013

DOI: 10.1002/14651858.CD006803.pub4


How to Cite

Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD006803. DOI: 10.1002/14651858.CD006803.pub4.

Author Information

  1. 1

    Royal Free Campus, UCL Medical School, Department of Surgery, London, UK

  2. 2

    Royal Free Hampstead NHS Foundation Trust and UCL Institute of Liver and Digestive Health, Sheila Sherlock Liver Centre, London, UK

  3. 3

    University College London, Division of Surgery & Interventional Science, London, London, UK

  4. 4

    Athens Medical Group, Hospital P. Faliro, GI and Hepatology, Athens, Greece

  5. 5

    Royal Free Hampstead NHS Foundation Trust, Sheila Sherlock Liver Centre, London, UK

*Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, UK. k.gurusamy@ucl.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 4 DEC 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Aguilera 2011 {published data only}
  • Aguilera V, Prieto M, Rubin A, Risalde B, Ortiz C, Gimenez M, et al. Prospective randomized trial comparing pegIFNalpha 2a and pegIFN alpha 2b with ribavirin in HCV-liver transplant recipients with recurrent hepatitis C. American Journal of Transplantation 2011;11(Suppl S2):275.
  • Aguilera V, Prieto M, Rubin A, Risalde B, Ortiz Canto C, Berenguer M. Prospective randomized trial comparing pegIFN alpha 2A and pegIFN alpha 2B with ribavirin in HCV-liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 2010;52(Suppl 1):S184.
  • Ortiz C, Lopez-Labrador FX, Canada R, Risalde B, Aguilera V, Prieto M, et al. Prospective randomized study of antiviral therapy post-transplantation: Effect of the type of Pegylated IFN and baseline immunosuppression. Liver Transplantation 2009;15(Suppl S7):S130.
Angelico 2007 {published data only}
  • Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 2007;46(6):1009-17.
  • Petrolati A, Lionetti R, Donato F, Merli M, Burra P, Angeli P, et al. Peg-interferon A-2A (40KD) with or without ribavirin in the treatment of naive patients with recurrent hepatitis C after liver transplantation. Liver Transplantation 2006;12(5):C-113.
  • Petrolati A, Lionetti R, Donato F, Merli M, Burra P, Angeli P, et al. Peginterferon alfa-2a (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Preliminary report of a randomized study [EASL abstract]. Journal of Hepatology 2004;40(Suppl 1):38.
  • Petrolati A, Lionetti R, Lenci I, Paolo DD, Donato F, Merli M, et al. Peg-interferon A-2A (40KD) with or without ribavirin in the treatment of naive patients with recurrent hepatitis C after liver transplantation. Hepatology 2005;42(4 Suppl 1):482A.
Belli 2012 {published data only}
  • Belli L, Volpes R, Graziadei I, Starkel P, Burroughs A, Burra P, et al. PEG-IFN-alfa 2b with ribavirin for the treatment of mild-moderate recurrent hepatitis C after liver transplantation (LT): Impact on fibrosis progression. A multicenter randomized controlled study. Hepatology 2009;50(4 Suppl):394a.
  • Belli LS, Volpes R, Graziadei I, Fagiuoli S, Starkel P, Burra P, et al. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and Liver Disease 2012;44(7):603-9.
Calmus 2012 {published data only}
  • Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, et al. Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of pegIFNalpha-2a plus ribavirin. Journal of Hepatology 2012;57(3):564-71.
Carrion 2007 {published data only}
  • Carrion JA, Garcia-Retortillo M, Navasa M, Rimola A, Garcia-Valdecasas JC, Forns X. Efficacy and safety of antiviral therapy in liver transplant recipients with chronic hepatitis C. Journal of Hepatology 2005;42(Suppl 2):47-8.
  • Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on disease progression in hepatitis C recurrence after liver transplantation: A randomized controlled study. Journal of Hepatology 2007;46(Suppl 1):S39-40.
  • Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007;132(5):1746-56.
Chalasani 2005 {published data only}
  • Alpert E, Levy GA, Marotta P, Deschenes M, Yoshida E, Peck-Radosavljevic M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;42(2):506.
  • Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41(2):289-98.
  • Ferenci P, Peck-Radosavljevic M, Vogel W, Graziadei I, Riely C, Voigt MD, et al. 40 KDA Peginterferon Alfa-2A (PEGASYS) in post-liver transplant recipients with established recurrent hepatitis C: Preliminary results of a randomized multicenter trial (abstract). Hepatology 2001;34(4 Pt 2):406A.
  • Vogel W, Ferenci P, Fontana R, Arbor A, Saab S, LaBrecque D, et al. Peginterferon alfa-2A (40 kd) (PEGASYS) in liver transplant recipients with established recurrent hepatitis C: Interim results of an ongoing randomized multicenter trial [abstract]. Hepatology 2002;36(4 Pt 2):312A.
Cotler 2001 {published data only}
  • Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001;71(2):261-6.
  • Cotler SJ, Ganger DR, Kaur S, Rosenblate H, Jakate S, Sullivan DG, et al. Daily interferon therapy for the treatment of hepatitis C infection in liver transplant recipients [abstract]. Hepatology 1999;30(4 Pt 2):246A.
Crippin 1996 {published data only}
  • Crippin JS, Huang KS, Wright TL, Terrault N, Lucey ML, Poterucha J, et al. Efficacy of interferon alpha 2A (roferon-A) in the treatment of hepatitis C and G following liver transplantation: A prospective, randomized study [AASLD abstract]. Hepatology 1996;24(4 Pt 2):294A.
Gane 1998 {published data only}
  • Gane EJ, Lo SK, Portmann B, Lau JYN, Naoumov NN, Williams R. A randomised study of the safety and efficacy of ribavirin vs interferon monotherapy for recurrent HCV infection in liver transplant recipients. Hepatology 1996;24(4 Pt 2):293A.
  • Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27(5):1403-7.
Gane 2009 {published data only}
  • Gane E, Strasser SI, Crawford D, Ring J, Rizkalla B, Thompson S, et al. Combination therapy is superior to pegylated interferon monotherapy for the treatment of recurrent hepatitis C. Journal of Gastroenterology and Hepatology 2009;24(Suppl S2):A278.
  • Gane EJ, Strasser SI, Crawford DH, Ring JA, Rizkalla B, Thompson SJ, et al. A multicenter, randomized trial of combination pegylated interferon-alpha 2a plus ribavirin vs. pegylated interferon-alpha 2A monotherapy in liver transplant recipients with recurrent hepatitis C. Hepatology 2009;50(Suppl 4):393A-394A.
Ghalib 2000 {published data only}
  • Ghalib R, Pandula R, Kadhim TJ, Clark C, Ankoma-Sey V, Fouzia S, et al. Treatment of recurrent hepatitis C after liver transplantation with alpha-2B interferon plus ribavirin. Hepatology 2000;32(4 Pt 2):291A.
Ghalib 2006 {published data only}
  • Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Huston W, et al. Treatment of recurrent hepatitis C after liver transplantation. Liver Transplantation 2006;12(5):C-29.
  • Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Hutson W, et al. Increased LFTS/clinical liver failure in post OLT patients being treated with peg-IFN alfa-2b plus ribavirin for recurrent hepatitis C. Liver Transplantation 2009;15(Suppl S7):S186.
  • Ghalib R, Levine C, Hollinger B, Stribling R, Box T, Hutson W, et al. Sustained viral response using peg-inf alfa-2B plus ribavirin in patients with recurrent hepatitis C after liver transplantation. Hepatology 2006;44(4 Suppl 1):478A.
  • Ghalib R, Levine C, McClelland T, Hollinger B, Stribling R, Box T, et al. Factors predictive of 24 week viral response to peg IFN alfa-2B plus ribavirin in patients with recurrent hepatitis C after liver transplantation. Hepatology 2004;40(4 Suppl 1):358A.
  • Ghalib RH, Levine CD, Hollinger FB, Stribling R, Box TD, Hutson W, et al. Increased LFTS/clinical liver failure in post OLT patients being treated with pegIFN alfa-2B plus ribavirin for recurrent hepatitis C. Gastroenterology 2009;5(Suppl 1):A811-2.
Gordon 2005 {published data only}
  • Gordon FD, Morin D, Davis C, Trabucco A, Simpson MA, Pomposelli JJ, et al. High sustained virological response (SVR) in HCV treatment with peginterferon-alfa 2b (PEG) and ribavirin (RBV) after liver transplantation (LT). American Journal of Transplantation 2005;5(S11):181.
Lodato 2008 {published data only}
Nair 2008 {published data only}
  • Nair S, Lipscomb J, Eason J. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation 2008; Vol. 86, issue 3:418-22. [0041-1337]
  • Nair S, Lipscomb J, Malloy H, Loss G, Cohen A, Eason J. Treatment of recurrent hepatitis C infection after liver transplantation: Randomized controlled trial of peg interferon alpha 2b and ribavirin vs. peg interferon alpha 2b, ribavirin and amantadine. Gastroenterology 2004;126(4 Suppl 2):A699.
Samuel 2003 {published data only}
  • Samuel D, Bizollon T, Feray C, Roche B, Ahmed SNS, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003;124(3):642-50.
  • Samuel D, Bizollon T, Feray C, Roche B, Lemonnier C, Plough S, et al. Combination of interferon alfa 2-B plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study. Hepatology 2000;32(4 Pt 2):295A.
Yedibela 2011 {published data only}

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Beckebaum 2003 {published data only}
  • Beckebaum S, Cicinnati VR, Karliova M, Dirsch O, Erim Y, Frilling A, et al. Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection. Transplantation Proceedings 2003;35(6):2080-1.
Beckebaum 2004 {published data only}
  • Beckebaum S, Cicinnati VR, Zhang X, Malago M, Dirsch O, Erim Y, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplantation Proceedings 2004;36(5):1489-91.
Boillot 1995 {published data only}
  • Boillot O, Berger F, Rasolofo E, Mion F, Chevallier P, Gille D, et al. Effects of early interferon alfa therapy for hepatitis C virus infection recurrence after liver transplantation. Transplantation Proceedings 1995;27(4):2501.
Casanovas 2004 {published data only}
Castedal 2003 {published data only}
  • Castedal M, Siewert DA, Olausson M, Friman S. Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation. Transplantation Proceedings 2003;35(2):820-1.
Catalano 2003 {published data only}
  • Catalano G, Urbani L, Oliveri F, Iaria G, Biancofiore G, Mosca F, et al. Recurrence of hepatitis C in liver transplants from elderly donors aged more than 75 years. Transplantation Proceedings 2003;35(3):1034.
Ceccherini 2003 {published data only}
  • Ceccherini NL, Giannotti A, Malizia T, Ciccorossi P, Olivieri F, Vanni M, et al. Recurrence of HCV infection in liver transplant patients: Evaluation of IgM anti-HCV and IgM anti-CMV. Transplantation Proceedings 2003;35(3):1030-1.
Crippin 2002 {published data only}
Dumortier 2002 {published data only}
Duvoux 2006 {published data only}
  • Calmus Y, Duvoux C, Samuel D, Pageaux GP, Messner M, Wolf P, et al. Multicenter randomized trial of HCV treatment with peginterferon-alfa 2a and ribavirin after liver transplantation: One-year report. Hepatology 2005;42(4 Suppl 1):487A.
  • Calmus Y, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al. Multicenter randomized trial in HCV-Infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation (TRANSPEG): Role of erythropoietin (Epo) on viral response. American Journal of Transplantation 2007;7(Suppl 2):372.
  • Calmus Y, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al. Multicenter randomized trial in HCV-infected patients treated with peginterferon alfa-2A and ribavirin followed by ribavirin alone after liver transplantation: 18-month report. Hepatology 2006;44(4 Suppl 1):189A.
  • Duvoux C, Samuel D, Pageaux G, Messner M, Wolf P, Rostaing L, et al. Multicenter randomized trial of HCV treatment with peginterferon-alpha 2a and ribavirin in liver transplant patients with established recurrent hepatitis C: Interim analysis. Journal of Hepatology 2006;44(Suppl 2):S3.
Fontana 2007 {published data only}
Israeli 2001 {published data only}
  • Israeli E, Galun E, Eid A, Ilan Y, Ashur Y, Jurim O, et al. Combination therapy for hepatitis C virus reinfection after orthoptic liver transplantation. Transplantation Proceedings 2001;33(6):2929.
Kizilisik 1997 {published data only}
Pinna 2001 {published data only}
  • Pinna AD, Ricordi C, Weppler D, Ruiz P, Tzakis AG. Treatment of recurrent hepatitis C after liver transplantation with IL-2r Ab. Transplantation Proceedings 2001;33(1-2):1087-9.
Samuel 2002 {published data only}
  • Samuel D, Roche B, Feray C. Treatment of hepatitis C virus infection after liver transplantation. Gastroenterologie Clinique et Biologique 2002;26(Spec 2):B231-7.
Samuel 2004 {published data only}
Samuel 2005 {published data only}
Samuel 2007 {published data only}
  • Samuel D, Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. Journal of Hepatology 2007;46(6):988-91.
Shakil 1999 {published data only}
  • Shakil O, Rakela J. Interferon-alfa2B and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C A [abstract]. Hepatology 1999;30(4 Pt 2):656A.
Shakil 2004 {published data only}
  • Shakil AO, Habib S, Berk B, Eghtesad B, Marcos A, Fung JJ. A trial of pegylated interferon and ribavirin among liver transplant recipients with hepatitis C: Reasons for screening failure and low enrollment. Hepatology 2004;40(4 Suppl 1):360A.
Taltavull 2004 {published data only}
Targhetta 2001 {published data only}
  • Targhetta S, Burra P, Popovic A, Silverj E, Pevere S, Russo FP, et al. Natural alpha-IFN in HCV recurrence after liver transplantation. Transplantation Proceedings 2001;33(1-2):1457-8. [0041-1345: (Print)]
Testino 2006 {published data only}
  • Testino G, Sumberaz A, Ravetti G, Gentile R, Ansaldi F, Icardi G. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: Relationship with steatosis. Digestive Liver Diseases 2006;38(11):864-5.
Vargas 1995 {published data only}
  • Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplantation Proceedings 1995;27(1):1222-3.
Wietzke 2000 {published data only}

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Afdhal 2004
  • Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126(5):1302-11.
Arjal 2007
Berenguer 2003
Bombuy 2004
  • Bombuy E, Fondevila C, Rodriguez-Laiz G, Ferrer J, Amador A, Valentini M, et al. Ischemic preconditioning in adult living donor liver transplantation, a pilot study [EASL abstract]. Journal of Hepatology 2004;40(Suppl 1):39.
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
Brok 2009
  • Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
Cameron 2006
  • Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Annals of Surgery 2006;244(4):563-71.
Cescon 2006
CONSORT 2009
  • The CONSORT Group. Transparent reporting of trials, 2009. www.consort-statement.org/equator-network-news-feb-2009/ (accessed on 18 November 2013).
Corno 2006
CTU 2011
  • Copenhagen Trial Unit. TSA - trial sequential analysis, 2011. ctu.dk/tsa/ (accessed 18 November 2013).
DeMets 1987
DerSimonian 1986
Dieterich 2003
  • Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology 2003;98(11):2491-9.
Eason 2001
Egger 1997
Forman 2002
  • Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122(4):889-96.
Ghobrial 1999
  • Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Annals of Surgery 1999;229(6):824-31; discussion 831-3.
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 9. Art. No.: LIVER.
Gurusamy 2009b
Gurusamy 2013
  • Gurusamy KS, Tsochatzis E, Toon C, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database of Systematic Reviews 2013, issue Under editorial. [DOI: 10.1002/14651858.CD006573.pub3]
Higgins 2002
Higgins 2008
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Kjaergard 2001
Koneru 2005
Lim 2006
  • Lim SG, Wai CT, Da Costa M, Sutedja DS, Lee YM, Lee KH, et al. Referral patterns and waiting times for liver transplantation in Singapore. Singapore Medical Journal 2006;47(7):599-603.
Lundh 2012
Macaskill 2001
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
Newell 1992
NHSBT
  • NHS Blood and Transplant - Organ Donation and Transplantation 2012-2013. http://www.organdonation.nhs.uk/statistics/transplant_activity_report/current_activity_reports/ukt/activity_report_2012_13.pdf (accessed 20 November 2013).
OPTN/SRTR 2009
  • The Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients. OPTN/SRTR 2009 annual report, 2009. www.ustransplant.org/annual_reports/current/905_li.pdf (accessed 18 November 2013).
Parmar 1998
Picciotto 2007
  • Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. Journal of Hepatology 2007;46(3):459-65.
RevMan 2008 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: Rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Savović 2012
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savović 2012a
  • Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Sharma 2007
Sharvadze 2006
  • Sharvadze L, Tsertsvadze T, Gochitashvili N, Kakabadze T, Dolmazashvili E. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. Georgian Medical News 2006;137:62-5.
Sharvadze 2007
  • Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Georgian Medical News 2007;147:52-5.
SPIRIT 2013
  • Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158:200-7.
SPIRIT 2013a
  • Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: Guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586.
StatsDirect 2.7 [Computer program]
  • StatsDirect Ltd. StatsDirect Statistical software Version 2.7.7. StatsDirect Ltd, 2009.
Sugo 2003
  • Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surgery Today 2003;33(6):421-5.
Thorlund 2009
  • Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 18 November 2013).
Triantos 2005
  • Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy. Transplantation 2005;79(3):261-8.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Gurusamy 2009a
Gurusamy 2010